STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 4, October-December 2020
REVIEWS
THERAPEUTIC POTENTIAL OF MTOR INHIBITORS IN PATIENTS WITH SARS-COV-2
GARCÍA MOLINA ANTONIO, FERRIOLS LISART RAFAEL, SÁNCHEZ MARTÍNEZ RUBÉN, GOMEZ PERALEZ ÁLVARO, PONCE ORTEGA PILAR


The novel coronavirus pandemic is spreading globally, and the whole world is facing a serious public health crisis. It is therefore of urgent importance to understand the pathophysiology of the disease in order to find a treatment that reduces the mortality rate and eases pressure on health systems. Here we review the possible therapeutic utility of mTOR inhibitors in patients with COVID-19, based on molecular characteristics, immunological profile and clinical data available for these drugs. Inhibition of the mTOR pathway decreases macrophage and neutrophil
activation, as well as their migration to the inflammatory focus. Furthermore, mTOR inhibition reduces the release of cytokines such as IL-6, IL-10, TNF-α, which have been shown to be elevated in severe patients.

CORONAVIRUS – MTOR PROTEIN – RAPAMYCIN – THERAPEUTICS



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25